MDUFMA Retains Center Stage In FY ’05, With Postmarket In Supporting Role
This article was originally published in The Gray Sheet
Executive Summary
CDRH Director Dan Schultz, MD, plans to preserve the strategic framework his predecessor envisioned for the device center
You may also be interested in...
CDRH To Consider Future Priorities In New “Stabilized” User Fee Climate
CDRH senior staff will meet in late August to iron out fiscal year 2006 priorities now that they have a clearer picture of expected user fee revenues
CDRH To Consider Future Priorities In New “Stabilized” User Fee Climate
CDRH senior staff will meet in late August to iron out fiscal year 2006 priorities now that they have a clearer picture of expected user fee revenues
OIVD Creates Internal Adverse Events Database; CoA Requirements Rare
FDA's in vitro diagnostics office recently established an in-house adverse events database to make a wider selection of post-approval information available to OIVD premarket review staff